• Home
  • Study Details
By physician referral or invitation only

Comparative effectiveness and safety of belatacept among kidney transplant recipients

Belatacept is a drug that helps kidney transplant recipients by preventing the body from rejecting the new organ. We want to compare how well belatacept works compared to the commonly used drug tacrolimus. To do this, we plan to study people who got kidney transplants in the United States from 2011 to 2020. By using two large databases, the United States Renal Data System, and the Scientific Registry of Transplant Recipients, we aim to understand how belatacept is used in real life. We are also interested in comparing how effective and safe is belatacept compared with tacrolimus after one year of administration. We will look at outcomes like how long the transplanted kidney will work, how long will the kidney transplant recipients live, how well your kidneys will work, the risk of organ rejection, and certain side effects to happen after transplant like blood cancer.

Age & Gender

  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study is recruiting by invitation only.

United States (Nationwide)

Additional Study Information

Principal Investigator

Sherin Ismail Atta
Epidemiology

Study Type

Clinical or Medical
Observational

Study Topics

Immune System/Infections
Kidneys and Liver
Transplant

IRB Number

24-0145

Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research